A retrospective study: Effects of additional SGLT2-inhibitor therapy on renal functions in patients with type 2 diabetes mellitus and stage 3b and 4 chronic kidney disease - Renal benefits of SGLT2-inhibitors in advanced CKD

We analyzed 42 T2DM patients with median GFR of 40.4 mL/min/1.73 m2. The annual decline in eGFR improved significantly after SGLT2 inhibitor therapy (eGFR: (median), pre: -3.8, vs. post: 0.1 mL/min/1.73 m2 per year, P < 0.01). We also found a significant decrease in urinary protein excretion after SGLT2 inhibitor therapy (urinary protein-to-creatinine ratio: (median), pre: 0.36, vs. post: 0.23 g/g creatinine, n = 35, P < 0.01).